• 2025
• 2024
• 2023
• 2022
• 2021
• 2020
• 2019
• 2018
• 2017
• 2016
• 2015
• 2014
• 2013
• 2012
• 2011
• 2010
• 2009
• 2008
• 2007
• 2006
• 2005
• 2004
• 2003
• 2002
• 2001
• 2000
• 1999
• 1998
• 1997
• 1996
• 1995
• 1993

2025

• Luecht, Ulrich Ruben, Scholz, Wolfgang Geiben Ann-Kathrin, and Haen, Ekkehard and Hempel Georg. 2025. “Physiologically Based Pharmacokinetic Model of CYP2D6 Associated Interaction Between Venlafaxine and Strong Inhibitor Bupropion—The Influence of Age-Relevant Changes and Inhibitory Dose to Classify Therapeutical Success and Harm.” Pharmaceutics 17 (2): 179–179. doi: 10.3390/pharmaceutics17020179.
• Opitz, Patrick, Waltering, Isabel, and Hempel, Georg. 2025. “Development and Validation of a Quantification Method for Direct Oral Anticoagulants from Capillary Blood using volumetric absorptive microsampling and online SPE-LC-MS.” Journal of Chromatography B 1251 124423. doi: 10.1016/j.jchromb.2024.124423.
• Zimbelmann F, Groll AH, Hempel G.. 2025. “Determination of Fluconazole in Children in Small Blood Volumes Using Volumetric Absorptive Microsampling (VAMS) and Isocratic High-Performance Liquid Chromatography–Ultraviolet (HPLC–UV) Detection.” Pharmaceutics 17 (5): 592. doi: 10.3390/pharmaceutics17050592.

2024

• Zimbelmann, F, Flaute, S, Deipenbrock, M, Ahlke, E, Hempel, G, and Baumann-Köhler, M. 2024. “Anwendung stark wirksamer retardierter Opioide in der Pädiatrie : Fallstricke und Lösungen für Morphin und Hydromorphon.” Der Schmerz 204. doi: 10.1007/s00482-023-00775-w.
• Bauch, T, and Hempel, G. 2024. “Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia.” British Journal of Haematology 204 (6): 2324–2331. doi: 10.1111/bjh.19410.
• Opitz, P, Fobker, M, Fabian, J, and Hempel, G. 2024. “Development and validation of a bioanalytical method for the quantification of methotrexate from serum and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS.” Journal of Chromatographic Science 1715 464610. doi: 10.1016/j.chroma.2023.464610.
• Ramadan, O.[1], Opitz, P.[2 3], and Hempel, G.[4]. 2024. “Development and Validation of a High-Performance Liquid Chromatography With Ultraviolet Detection Method to Facilitate Therapeutic Monitoring of Teicoplanin Using Dried Blood Spots.” Therapeutic Drug Monitoring 00: 1–7. doi: 10.1097/FTD.0000000000001202.

2023

• Schatz, LM, Brinkmann, A, Röhr, A, Frey, O, Greppmair, S, Weinelt, F, Zoller, M, Scharf, C, Hempel, G, and Liebchen, U. 2023. “Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.” Antimicrobial Agents and Chemotherapy 1. doi: 10.1128/aac.00104-23.
• Rosser, SPA, McLachlan, AJ, Hempel, G, Chung, J, Shaw, PJ, Keogh, SJ, and Nath, CE. 2023. “Validation of a liquid chromatography-tandem mass spectrometry method for simultaneous quantification of N,N-dimethylacetamide and N-monomethylacetamide in pediatric plasma.” Journal of Separation Science 46 (10). doi: 10.1002/jssc.202201003.
• Ramadan O, Schatz LM, van den Heuvel I, Masjosthusmann K, Groll AH, Hempel G. 2023. “Developing a Method for Quantifying Meropenem in Children-Volumetric Adsorptive Microsampling Versus Plasma Sampling.” Therapeutic Drug Monitoring 45 (5): 623–630.
• Gastine, SE; Rauwolf, KK; Pieper, S; Hempel, G; Lehrnbecher, T; Tragiannidis, A; Groll, AH. 2023. “Voriconazole plasma concentrations and dosing in paediatric patients below 24 months of age.” Mycoses 66 (11): 969–976.
• Maierhöfer, S, Waltering, I, Würthwein, G, Jacobs, M, and Hempel, G. 2023. “Ein klinisches Entscheidungsunterstützungssystem für Medikationsanalysen in öffentlichen Apotheken: patientenberichtete Endpunkte der OPtiMed-Studie.” contributed to the Annual Meeting of the German Society of Clinical Pharmacy – DGKPha, Münster.
• Opitz, P, Zimmermann, S, Stapf, M, Klima, F, Müller, L, Fuxius, S, Illerhaus, G, Scherf-Clavel, O, Kloft, C, and Hempel, G. 2023. “Erweiterung einer bioanalytischen Methode für das therapeutische Drug Monitoring von Axitinib in Plasma und Kapillarblut zu einer generischen Methode für orale Onkologika.” contributed to the Jahrestagung der Deutschen Gesellschaft für Klinische Pharmazie DGKPha, Münster.

2022

• Khalil, A, Würthwein, G, Golitsch, J, Hempel, G, Fobker, M, Gerss, J, Möricke, A, Zimmermann, M, Smisek, P, Zucchetti, M, Nath, C, Attarbaschi, A, Von Stackelberg, A, Gökbuget, N, Rizzari, C, Conter, V, Schrappe, M, Boos, J, and Lanvers-Kaminsky, C. 2022. “Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.” Haematologica 107 (1). doi: 10.3324/haematol.2020.258525.
• Bognàr, T, Bartelink, IH, Egberts, T, Rademaker, C, Versluys, B, Slatter, MA, Kletzel, M, Nath, CE, Cuvelier, GDE, Savic, RM, Dvorak, C, Long-Boyle, JR, Cowan, MJ, Bittencourt, H, Bredius, M, Güngör, T, Shaw, PJ, Ansari, M, Hassan, M, Krajinovic, M, Hempel, G, Marktel, S, Chiesa, R, Théoret, Y, Lund, T, Orchard, PJ, Wynn, RRF, Boelens, J, and Lalmohamed, A. 2022. “Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation.” Cellular Therapy and Transplantation 22. doi: 10.1016/j.jtct.2022.01.013.
• Khalil, A; Würthwein, G; Golitsch, J; Hempel, G; Fobker, M; Gerss, J; Möricke, A; Zimmermann, M; Smisek, P; Zucchetti, M; Nath, C; Attarbaschi, A; Von Stackelberg, A; Gökbuget, N; Rizzari, C; Conter, V; Schrappe, M; Boos, J; Lanvers-Kaminsky, C. 2022. “Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.” Haematologica 107 (1): 49–57. doi: 10.3324/haematol.2020.258525.
• Opitz, Patrick, Zimmermann, Sebastian, Mc Laughlin, M.Anna, Müller, Lothar, Fuxius, Stefan, Illerhaus, Gerald, Scherf-Clavel, Oliver, Kloft, Charlotte, and Hempel, Georg. 2022. “Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS.” Journal of Pharmaceutical and Biomedical Analysis 221 115033. doi: 10.1016/j.jpba.2022.115033.
• Lea, Marie Schatz, Georg, Hempel, Ferdinand, Anton Weinelt, and Uwe, Liebchen. 2022. “Systematic evaluation of meropenem pharmacokinetic models for Bayesian forecasting in critically ill patients undergoing continuous renal replacement therapy.” contributed to the Quantitative Systems Pharmacology Conference 2022, Leiden.
• Schatz, Lea Marie, Wicha, Sebastian G., Hempel, Georg, de Hoog, Matthijs, Allegaert, Karel, Knibbe, CatherijneA.J, and Völler, Swantje. 2022. “Model-informed precision dosing for vancomycin in children between 28 days and 18 years: Does the use of a multi-model approach improve the predictive performance?” contributed to the Population Approach Group Europe 2022 (PAGE), Ljubljana.
• Hirn-Derksen, B., Ryu, C., Hyunki, C., Kim, J.Y., and Hempel, G. 2022. “Development of a pharmacokinetic model to predict disposition of Dutasteride in zebrafish embryos.” contributed to the Population Approach Group Europe 2022 (PAGE), Ljubljana.
• Shahhossini, Morwarid, Lehmann, Florian, Schmidt, Christina, Arnemann, Philip-Helge, Kaiser, Luca Elisa, Ertmer, Christian, Hempel, Georg, and Hessler, Michael. 2022. “Plasmakonzentration von Vancomycin nach Hämadsorption mit Cytosorb®.” contributed to the Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI), Hamburg.
• Morwarid, Shahhossini., Hessler, Michael, and Hempel, Georg. 2022. “Development of a physiologically based pharmacokinetic model of Ciprofloxacin in ovine septic shock.” contributed to the Population Approach Group Europe 2022 (PAGE), Ljubljana.
• Mohamed, Fakry F., Anhlan, Darisuren, Schöfbänker, Michael, Schreiber, André, Classen, Nica, Hensel, Andreas, Hempel, Georg, Scholz, Wolfgang, Kühn, Joachim, and Hrincius, Eike R. Stephan Ludwig. 2022. “Hypericum perforatum and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2.” Pharmaceuticals 15 (5). doi: 10.3390/ph15050530.
• Maierhöfer, S; Waltering, I; Jacobs, M; Würthwein, G; Appelrath, M; Koling, S; Hempel, G. 2022. “Decision support software-guided medication reviews in elderly patients with polypharmacy: a prospective analysis of routine data from community pharmacies (OPtiMed study protocol).” Journal of Pharmaceutical Policy and Practice 15 (1). doi: 10.1186/s40545-022-00495-z.
• Maierhöfer, S, Waltering, I, Jacobs, M, Appelrath, M, and Hempel, G. 2022. “Developing a questionnaire comprising clinically useful patient-reported outcome measures in software-assisted medication reviews.” contribution to the Jahrestagung der deutschen Gesellschaft für klinische Pharmazie, Heidelberg

2021

• Opitz, Patrick, Stern, Mike, and Hempel, Georg. 2021. “Entwicklung und Validierung einer quantitativen Methode zur Bestimmung von direkten oralen Antikoagulantien aus Kapillarblut unter Verwendung von VAMSTM und online SPE-LC-MS.” contributed to the Deutschen Gesellschaft für Klinische Pharmazie (DGKPh), digital.
• Rimmler, Ch, Lanckohr, Ch, Mittrup, M, Welp, H, Würthwein, G, Horn, D, Fobker, M, Ellger, B, and Hempel, G. 2021. “Population pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis during and after cardiopulmonary bypass.” British Journal of Clinical Pharmacology 87 (3): 1486–1498.
• Mc, Laughlin AM, Schmulenson, E, Teplytska, O, Zimmermann, S, Opitz, P, Groenland, SL, Huitema, ADR, Steeghs, N, Müller, L, Fuxius, S, Illerhaus, G, Joerger, M, Mayer, F, Fuhr, U, Holdenrieder, S, Hempel, G, Scherf-Clavel, O, Jaehde, U, and Kloft, C. 2021. “Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. For The On-Target Study Consortium.” Cancers 13 (24). doi: 10.3390/cancers1324628.
• Blume, H, Mehta, M, Beuerle, G, Dorantes, A, Hempel, G, Jiang, W, Kovar, A, Lee, J, Potthast, H, Schug, B, Seidlitz, A, Tampal, N, Tsang, Y, Walstab, J, and Welink, J. 2021. “The Global Bioequivalence Harmonisation Initiative (GBHI): Report of EUFEPS/AAPS fourth conference.” European Journal of Pharmaceutical Sciences 2021. doi: 10.1016/j.ejps.2021.105987.
• Barnett, S, Hellmann, F, Parke, E, Makin, G, Tweddle, DA, Osborne, C, Hempel, G, and Veal, GJ. 2021. “Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients.” European Journal of Cancer (1965) 2021. doi: 10.1016/j.ejca.2021.09.014.
• Jalusic, KO, Hempel, G, Arnemann, PH, Spiekermann, C, Kampmeier, TG, Ertmer, C, Gastine, S, and Hessler, M. 2021. “Population pharmacokinetics of vancomycin in patients with external ventricular drain-associated ventriculitis.” British Journal of Clinical Pharmacology 87 (6).
• Zubiaur, P, Kneller, LA, Ochoa, D, Mejía, G, Saiz-Rodríguez, M, Borobia, AM, Koller, D, García, IG, Navares-Gómez, M, Hempel, G, and Abad-Santos, F. 2021. “Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.” Clinical Pharmacokinetics 60 (2).
• Gastine, S, Hope, W, Hempel, G, Petraitiene, R, Petraitis, V, Mickiene, D, Bacher, J, Walsh, TJ, and Groll, AH. 2021. “Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.” Antimicrobial Agents and Chemotherapy 65 (2). doi: 10.1128/AAC.01574-20.
• Kneller, LA, Zubiaur, P, Koller, D, Abad-Santos, F, and Hempel, G. 2021. “Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.” Clinical Pharmacokinetics 2021 (Jun 14). doi: 10.1007/s40262-021-01041-x.
• Waltering, Isabell, Schwalbe, Olaf, and Hempel, Georg. 2021. “Identification of factors for a successful implementation of medication reviews in community pharmacies: Using Positive Deviance in pharmaceutical care.” International Journal of Clinical Pharmacy 44 (1). doi: 10.1007/s11096-021-01315-1.
• Spiegler, V, Greiffer, L, Jacobtorweihen, J, Asase, A, Lanvers-Kaminsky, C, Hempel, G, Agyare, C, and Hensel, A. 2021. “In vitro screening of plant extracts traditionally used as cancer remedies in Ghana - 15-Hydroxyangustilobine A as the active principle in Alstonia boonei leaves.” Journal of Ethnopharmacology 265. doi: 10.1016/j.jep.2020.113359.
• Würthwein, G, Lanvers-Kaminsky, C, Siebel, C, Gerß, J, Möricke, A, Zimmermann, M, Stary, J, Smisek, P, Schrappe, M, Rizzari, C, Zucchetti, M, Hempel, G, Wicha, SG, and Boos, J. 2021. “Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data.” European Journal of Drug Metabolism and Pharmacokinetics 46 (2): 289–300. doi: 10.1007/s13318-021-00670-8.
• Shahhossini, Morwarid, Hessler, Michael, and Hempel, Georg. 2021. “Untersuchung der Adsorption von Ciprofloxacin in vivo nach Hämoadsorption mit CytoSorb®.” contributed to the Deutschen Gesellschaft für Klinische Pharmazie (DGKPh), digital.
• Schatz, L.M., Ramadan, O., Groll, A., Masjosthusmann, K., van den Heuvel, A., and Hempel, G. 2021. “Therapeutisches Drug Monitoring und Dosisoptimierung von Meropenem, basierend auf kleinen Probenvolumina bei kritisch kranken Kindern.” contributed to the Deutschen Gesellschaft für Klinische Pharmazie (DGKPh), online.
• Maierhöfer, S, Waltering, I, Gillessen, A, Würthwein, G, and Hempel, G. 2021. “Effekte Software-gestützter Medikationsanalysen auf die Angemessenheit der Medikation und auf patientenberichtete Endpunkte bei geriatrischen Patienten mit Polypharmazie: eine prospektive Analyse von Routinedaten aus öffentlichen Apotheken (OptiMed- Studienprotokoll).” contributed to the Annual Meeting of the German Society of Clinical Pharmacy - DGKPha, München.
• Maierhöfer, S, Waltering, I, Riebel, S, and Hempel, G. 2021. “Effectiveness of clinical decision support systems for managing drug therapy: a systematic review within the scope of a clinical evaluation of a medical device.” contributed to the 12th PCNE working conference, Basel. doi: 10.1007/s11096-21-01269-4.
• McLaughlin1, A.M., Schmulenson2, E, Teplytska2, O, Zimmermann3, S, Opitz, P, Groenland4, S.L., Huitema45, A.D.R., Steeghs4, N., Müller6, L., Fuxius7, S., Illerhaus8, G., Joerger9, M., Mayer10, F., Fuhr11, U., Holdenrieder12, S., Hempel, G., Scherf-Clavel3, O., Jaehde2, U., and Kloft1, C. 2021. “Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.” Cancers 13 (24): 1–15. doi: 10.3390/cancers13246281.

2020

• Stern, M, Giebels, M, Fey, T, Lübking, M, Alferink, J, and Hempel, G. 2020. “Validation and clinical application of a volumetric absorptive microsampling method for 14 psychiatric drugs.” Bioanalysis 2020 Aug;12(16). doi: 10.4155/bio-2020-0136.
• Hempel, G. 2020. “Methods of Therapeutic Drug Monitoring including Pharmacogenetics 2nd Edition.” in Handbook of Analytical Separations Series Volume 7:, edited by Elsevier B.V. Amsterdam.
• Hensel, A, Bauer, R, Heinrich, M, Spiegler, V, Kayser, O, Hempel, G, and Kraft, K. 2020. “Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.” Planta Medica 2020.
• Hempel, G. 2020. “How physiologically-based pharmacokinetic models should be improved for drug development.” Future Medicinal Chemistry 12 (12). doi: 10.4155/fmc-2020-0074.
• Siebel, C, Würthwein, G, Lanvers-Kaminsky, C, André, N, Berthold, F, Castelli, I, Chastagner, P, Doz, F, English, M, Escherich, G, Frühwald, MC, Graf, N, Groll, AH, Ruggiero, A, Hempel, G, and Boos, J. 2020. “Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure.” BMC pharmacology & toxicology 21 (1). doi: 10.1186/s40360-020-00417-2.
• Dallmann, A, Himstedt, A, Solodenko, J, Ince, I, Hempel, G, and Eissing.T. 2020. “Integration of physiological changes during the postpartum period into a PBPK framework and prediction of amoxicillin disposition before and shortly after delivery.” Journal of Pharmacokinetics and Pharmacodynamics 47 (4).
• Hellmann, F, Völler, S, Krischke, M, Jamieson, D, André, N, Bisogno, G, Boddy, A, and Hempel, G. 2020. “Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the "European Paediatric Oncology Off-patents Medicines Consortium" (EPOC) Trial.” European Journal of Drug Metabolism and Pharmacokinetics 45 (3).
• Berning, P, Hennemann, C, Tulotta, C, Schaefer, C, Lechtape, B, Hotfilder, M, El, Gourari Y, Jürgens, H, Snaar-Jagalska, E, Hempel, G, Dirksen, U, and Potratz, J. 2020. “The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma.” Cancers 12 (4).
• Kneller, LA, and Hempel, G. 2020. “Physiologically based pharmacokinetic modelling of risperidone and 9-hydroxyrisperidone to determine cytochrome P450 2D6 phenotypes in schizophrenia patients.” in Vol. 53 of Pharmacopsychiatry 2020 Stuttgart · New York: Georg Thieme Verlag KG. doi: 10.1055/s-0040-1710122.
• Kneller, LA, Abad-Santos, F, and Hempel, G. 2020. “Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.” Clinical Pharmacokinetics 59 (1). doi: 10.1007/s40262-019-00793-x.
• Kneller, LA, and Hempel, G. 2020. “Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.” Pharmaceutical Research 37 (6). doi: 10.1007/s11095-020-02843-7.
• Zubiaur, P, Kneller, LA, Ochoa, D, Mejía, G, Saiz-Rodríguez, M, Borobia, AM, Koller, D, García, IG, Navares-Gómez, M, Hempel, G, and Abad-Santos, F. 2020. “Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.” Clinical Pharmacokinetics 60 (2). doi: 10.1007/s40262-020-00941-8.
• Waltering, I, Scheppe, S, Kurth, V, Hempel, G, and Jaehde, U. 2020. “Qualitätsindikatoren zur Bewertung von Medikationsanalysen in öffentlichen Apotheken. (Quality indicators for medication reviews in community pharmacies).” Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 153-154. doi: 10.1016/j.zefq.2020.03.007.
• Stern, M, Giebels, M, Fey, T, Lübking, M, Alferink, J, and Hempel, G. 2020. “Validation and clinical application of a volumetric absorptive microsampling method for 14 psychiatric drugs.” Bioanalysis 12 (16). doi: 10.4155/bio-2020-0136.
• Stern, M, and Hempel, G. 2020. “Clinical validation study to derive conversion factors from capillary blood to plasma concentration for mirtazapine, quetiapine and norquetiapine.” contribution to the IATDMCT 2020, Canada
• Lücht, UR, Geiben, AK, Brune, S, Scholz, WU, and Hempel, G. 2020. “Using physiologically based pharmacokinetic (PBPK) modelling and SCHOLZ databank’s MDDI calculator (SDB-MDDI) to predict potential drug-drug interactions (DDI) of psychopharmaceuticals.” in Pharmacopsychiatry , Vol. 3 of 53 Stuttgart · New York: Georg Thieme Verlag KG. doi: 10.1055/s-0040-1710124.
• Siebel, Ch, Lanvers-Kaminsky, C, Würthwein, G, Hempel, G, and Boos, J. 2020. “Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring.” Scientific Reports 1 Vol (10): 18562.. doi: 10.1038/s41598-020-75662.
• Dellinger, JK, Pitzer, S, Schaffler-Schaden, D, Schreier, MM, Fährmann, LS, Hempel, G, Likar, R, Osterbrink, J, and Flamm, M. 2020. “Improving medication appropriateness in nursing homes via structured interprofessional medication-review supported by health information technology: a non-randomized controlled study.” BMC Geriatrics 20 (1): 506.. doi: 10.1186/s12877-020-01895-z.
• Siebel, C, Lanvers-Kaminsky, C, Würthwein, G, Hempel, G, and Boos, J. 2020. “Bioanalysis of doxorubicin aglycone metabolites in human plasma samples-implications for doxorubicin drug monitoring.” Scientific Reports 10 (1): 18562.. doi: 10.1038/s41598-020-75662-w.
• Khalil, A, Würthwein, G, Golitsch, J, Hempel, G, Fobker, M, Gerss, J, Möricke, A, Zimmermann, M, Smisek, P, Zucchetti, M, Nath, C, Attarbaschi, A, Stackelberg, A, Gökbuget, N, Rizzari, C, Conter, V, Schrappe, M, Boos, J, and Lanvers-Kaminsky, C. 2020. “Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.” Haematologica Online ahead of print. doi: 10.3324/haematol.2020.258525.

2019

• Lücht, UR, Weber, J, Scholz, WU, Brune, S, and Hempel, G. 2019. “Physiologically based pharmacokinetic modelling approach to assess drug-drug interactions (DDi) between psychopharmaceuticals - focus on mirtazapine and venlafaxine.” contribution to the XXVIIIth Meeting of the Population Approach Group Europe - PAGE, Stockholm, Sweden
• Hempel, G. 2019. “Pharmacotherapy in Children and Adolescents: Oncology.” in Handb Exp Pharmacol, edited by Springer. doi: 10.1007/164_2019_306.
• Lehrnbecher, T, Bochennek, K, Klingebiel, T, Gastine, S, Hempel, G, and Groll, AH. 2019. “Extended Dosing Regimens for Fungal Prophylaxis.” Clinical Microbiology Reviews 2019 (32(3)).
• Gastine, S, Lanckohr, C, Blessou, M, Horn, D, Fobker, M, Bause, D, Hempel, G, and Ellger, B. 2019. “Pharmacokinetics of Micafungin in Critically Ill Patients.” Scientific Reports 9(1). doi: 10.1038/s41598-019-53093-6.
• Jackson, RK, Liebich, M, Berry, P, Errington, J, Liu, J, Parker, C, Moppett, J, Samarasinghe, S, Hough, R, Rowntree, C, Goulden, NJ, Vora, A, Kearns, PR, Saha, V, Hempel, G, Irving, JAE, and Veal, GJ. 2019. “Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia-a report from the UKALL 2011 trial.” European Journal of Cancer 120. doi: 10.1016/j.ejca.2019.07.026.
• Freundt, JK, Frommeyer, G, Spieker, T, Wötzel, F, Grotthoff, JS, Stypmann, J, Hempel, G, Schäfers, M, Jacobs, AH, Eckardt, L, and Lange, PS. 2019. “Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure.” BMC pharmacology & toxicology 2019 (20(1)). doi: 10.1186/s40360-019-0294-x.
• Pinder, N, Zimmermann, JB, Gastine, S, Würthwein, G, Hempel, G, Bruckner, T, Hoppe-Tichy, T, Weigand, MA, and Swoboda, S. 2019. “Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic/pharmacodynamic study with population pharmacokinetic modeling.” Biomedicine & Pharmacotherapy 118 109318. doi: 10.1016/j.biopha.2019.109318.
• Kneller, LA, Abad-Santos, F, and Hempel, G. 2019. “Dose adjustment of risperidone in Cytochrome P450 2D6 intermediate- and poor metabolizer based on physiologically-based pharmacokinetic model.” contribution to the Annual Meeting of the German Pharmaceutical Society – DPhG, Heidelberg, Germany
• Kneller, LA, Abad-Santos, F, and Hempel, G. 2019. “Impact of Cytochrome P450 2D6, -3A4 and P-glycoprotein on risperidone’s and 9-Hydroxyrisperidone’s plasma concentrations using a whole-body PBPK approach.” contribution to the Annual Meeting of the population approach group in Europe [PAGE], Stockholm, Sweden

2018

• Völler, S, Pichlmeier, U, Zens, A, and Hempel, G. 2018. “Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.” Cancer Chemotherapy and Pharmacology 81 (2): 305–314. doi: 10.1007/s00280-17-3492-5.
• Dallmann, A, Ince, I, Coboeken, K, Eissing, T, and Hempel, G. 2018. “A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways.” Clinical Pharmacokinetics 57 (6): 749–768. doi: 10.1007/s40262-017-0594-5.
• Gastine, S, Lehrnbecher, T, Müller, C, Farowski, F, Bader, P, Ullmann-Moskovits, J, Cornely, OA, Groll, AH, and Hempel, G. 2018. “Pharmacokinetic modeling of variconazole to develop an alternative dosing regimen in children.” Antimicrobial Agents and Chemotherapy 62.
• Agyare, C, Spiegler, V, Asase, A, Scholz, M, Hempel, G, and Hensel, A. 2018. “An ethnopharmacological survey of medicinal plants traditionally used for cancer treatment in the Ashanti region, Ghana.” Journal of Ethnopharmacology 212: 137–152. doi: 10.1016/j.jep.2017.10.019.
• Lücht, UR, Weber, J, Rimmler, C, Scholz, WU, Brune, S, and Hempel, G. 2018. “Quantification of Pharmacokinetic Interactions: SCHOLZ Datenbank's MDDI-Calculator vs. Physiologically-Based Pharmacokinetic Modeling.” contribution to the Annual Meeting of the German Pharmaceutical Society - DPhG, Hamburg, Germany
• Kneller, LA, Abad-Santos, F, and Hempel, G. 2018. “Physiologically-based Pharmacokinetic Modelling of Risperidone and its Active Metabolite 9-Hydroxyrisperidone in Subjects Genotypes for Cytochrome P450 2D6.” contribution to the Annual Meeting of the German Pharmaceutical Society – DPhG, Hamburg, Germany
• Ellermann, I, Bueckmann, A, Eveslage, M, Buddendick, H, Latal, T, Niehoff, D, Geissler, RG, Hempel, G, Kerkhoff, A, Berdel, WE, Roeder, N, Van Aken, HK, Zarbock, A, and Steinbicker, AU. 2018. “Treating Anemia in the Preanaesthesia Assessment Clinic: Results of a Retrospective Evaluation.” Anesthesia and Analgesia 1. doi: 10.1213/ANE.0000000000003583.
• Völler, S, Pichlmeier, U, Zens, A, and Hempel, G. 2018. “Pharmacokinetics of recombinant asparaginase in children with achute lymphoblastic leukemia.” Cancer Chemotherapy and Pharmacology 81 (2): 305–314. doi: 10.1007/s00280-017-3492-5.
• Agyare, C, Spiegler, V, Asase, A, Scholz, M, Hempel, G, and Hensel, A. 2018. “An ethnopharmacological survey of medicinal plants traditionally used for cancer treatment in the Ashanti region, Ghana.” Journal of Ethnopharmacology 212: 137–152. doi: 10.1016/j.jep.2017.10.019.
• Perego, P, Hempel, G, Linder, S, Bradshaw, TD, Larsen, AK, Petres, GJ, and Philipps, RM. 2018. “Cellular pharmacology studies of anticancer agents:recommendations from the EORTIC-PAMM group.” Cancer Chemotherapy and Pharmacology 81 (3): 427–441. doi: 10.1007/s00280-017-3502-7.

2017

• Wähnert, Dirk, and Roos, AGlasbrenner J. Ilting-Reuke K. Ohrmann P. Hempel G. Duning T. Roeder N. Raschke M. 2017. “Alterstraumatologie: Multimodale Delirprävention und Verwendung von Augmentationstechniken.” Der Chirurg 88 (2): 95–104. doi: 10.1007/s00104-016-0339-2.
• Weber, J, Oberfeld, S, Bonse, A, Telger, K, Lingg, R, and Hempel, G. 2017. “Validation of a dried blood spot method for therapeutic drug monitoring of citalopram, mirtazapine and risperidone and its active metabolite 9-hydroxyrisperidone using HPLC–MS.” Journal of Pharmaceutical and Biomedical Analysis 2017 (140).
• Würthwein, G, Lanvers-Kaminsky, C, Hempel, G, Gastine, S, Möricke, A, Schrappe, M, Karlsson, MO, and Boos, J. 2017. “Population Pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar® in children with ALL.” contribution to the PAGE 26, Budapest, Ungarn
• Wähnert, D, Roos, A, Glasbrenner, J, Ilting-Reuke, K, Ohrmann, P, Hempel, G, Duning, T, Roeder, N, and Raschke, MJ. 2017. “Alterstraumatologie Multimodale Delirprävention und Verwendung von Augmentationstechniken.” Der Chirurg 88.
• Mahlknecht, A, Nestler, N, Bauer, U, Schüßler, N, Schuler, J, Scharer, S, Becker, R, Waltering, I, Hempel, G, Schwalbe, O, Flamm, M, and Osterbrink, J. 2017. “Effect of training and structured medication review on medication appropriateness in nursing home residents and on cooperation between health care professionals: the InTherAKT study protocol.” BMC Geriatrics 17 (1).
• Wähnert, D, Roos, A, Glasbrenner, J, Ilting-Reuke, K, Ohrmann, P, Hempel, G, Duning, T, Roeder, N, and Raschke, MJ. 2017. “Alterstraumatologie Multimodale Delirprävention und Verwendung von Augmentationstechniken.” Der Chirurg 88 (2): 95–104.
• Völler, S, Hempel, G, Würthwein, G, Boddy, AV, Krischke, M, André, N, D'Incalci, M, Bisogno, G, and Boos, J. 2017. “Towards a Model-Based Dose Recommendation for Doxorubicin in Children.” Clinical Pharmacokinetics 56 (3): 215–223. doi: 10.1007/s40262-016-0451-y.
• A, Dallmann, I, Ince, Solodenko, M, Meyer, S, Willmann, T, Eissing, and G, Hempel. 2017. “Physiological based pharmacokinetic modeling of renally cleared drugs in pregnant women.” Clinical Pharmacokinetics 2017. doi: 10.1007/s40262-017-0538-0.
• Dallmann, A, Ince, I, Meyer, M, Willmann, S, Eissing, T, and Hempel, G. 2017. “Gestation-specific changes in the anatomy and physiology of healthy pregnant women:an extended repository of model parameters for physiologically based pharmacokinetic modeling in pregnancy.” Clinical Pharmacokinetics 2017. doi: 10.1007/s40262-017-0539-z.
• Radke, C, Horn, D, Lanckohr, C, Ellger, B, Meyer, M, Eissing, T, and Hempel, G. 2017. “Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.” Clinical Pharmacokinetics 56. doi: 10.1007/s40262-016-0475-3.
• Würthwein, G, Lanvers-Kaminsky, C, Hempel, G, Gastine, S, Möricke, A, Schrappe, M, Karlsson, M, and Boos, J. 2017. “Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia.” European Journal of Drug Metabolism and Pharmacokinetics 42 (6): 955–963. doi: 10.1007/s13318-017-0410-5.
• Gastine, S, Lehrnbecher, T, Müller, C, Farowski, F, Bader, P, Ullmann-Moskovits, J, Cornely, OA, Groll, AH, and Hempel, G. 2017. “Pharmakokinetic Modeling of Voriconazole to Develop an Alternative Dosing Regimen in Children.” Antimicrobial Agents and Chemotherapy 62 (1). doi: 10.1128/AAC.01194-17.
• Dickschen, KJ, Willmann, S, Hempel, G, and Block, M. 2017. “Addressing Adherence Using Genotype-Specific PBPK Modeling-Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels.” Frontiers in Pharmacology 8. doi: 10.33380/fphar.2017.00067.

2016

• John, C, Herz, T, Boos, J, Langer, K, and Hempel, G. 2016. “Asymmetrical flow field-flow fractionation for the analysis of PEG-asparaginase.” Talanta 146: 335–339. doi: 10.1016/j.talanta.2015.08.028.
• Liebich, M, and Hempel, G. 2016. “Glucose as a cryoprotectant to stabilize liposomal daunorubicin (DaunoXome®) in frozen plasma for pharmacokinetic investigations.” contribution to the EORTC-PAMM Winter, Antwerpen, Begium
• Radke, C, Horn, D, Lanckohr, C, Ellger, B, Meyer, M, Eissing, T, and Hempel, G. 2016. “Development of a PBPK approach to predict the pharmacokinetics in patients with sepsis.” contribution to the PAGE, Lissabon,Portugal
• Waltering, I, Schwalbe, O, and Hempel, G. 2016. “Information content of medication schedules prior to the implementation of the federal standard medication plan.” Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 115-1.
• Krischke, M, Hempel, G, Völler, S, Andrè, N, D'Incalci, M, Bisogno, G, Köpcke, W, Borowski, M, Herold, R, Boddy, AV, and Boos, J. 2016. “Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" Trial.” Cancer Chemotherapy and Pharmacology 21.
• Bartelink, IH, Lalmohamed, A, van Reij, EM, Dvorak, CC, Savic, RM, Zwaveling, J, Bredius, RG, Egberts, AC, Bierings, M, Kletzel, M, Shaw, PJ, Nath, CE, Hempel, G, Ansari, M, Krajinovic, M, Thèoret, Y, Duval, M, Keizer, RJ, Bittencourt, H, Hassan, M, Güngör, T, Wynn, RF, Veys, P, Cuvelier, GD, Marktel, S, Chiesa, R, Cowan, MJ, Slatter, MA, Stricherz, MK, Jennissen, C, Long-Boyle, JR, and Boelens, JJ. 2016. “Association of busulfan eyposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.” The Lancet Haematology 13.
• Usman, M, and Hempel, G. 2016. “Development and validation of an HPLC method for the determination of vancomycin in human plasma and its comparison with an immunoassay (PETINIA).” SpringerPlus 5. doi: 10.1186/s40064-016-1778-4.
• John, C, Herz, T, Boos, J, Langer, K, and HempelG. 2016. “Asymmetrial flow field-flow fractionation for the analysis of PEG-asparaginase.” Talanta 146: 335–339.
• Lanckohr, C, Horn, D, Voeller, S, Hempel, G, Fobker, M, Welp, H, Koeck, R, and Ellger, B. 2016. “Pharmacokinetic characteristics and microbiologic appropriateness of cefazolin for perioperative antibiotic prophylaxis in elective cardiac surgery.” Journal of Thoracic and Cardiovascular Surgery 152 (2): 603–610. doi: 10.1016/j.jtcvs.2016.04.024.
• Krischke, M, Hempel, G, Völler, S, André, N, D’Incalci, M, Bisogno, G, Köpcke, W, Borowski, M, Herold, R, Boddy, AV, and Boos, J. 2016. “Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a ‘European Pediatric Oncology Off-patents Medicines Consortium’ trial.” Cancer Chemotherapy and Pharmacology 78 (6): 1175–1184. doi: 10.1007/s00280-016-3174-8.

2015

• Henrichsmann, M, and Hempel, G. 2015. “Impact of medication therapy management in patients with Parkinson's disease.” International Journal of Clinical Pharmacy 38 (1): 54–60. doi: 10.1007/s11096-015-0206-0.
• Goedecke, S, Mühlisch, J, Hempel, G, Frühwald, MC, and Wünsch, B. 2015. “Quantitative analysis of DNA methylation in the promoter region of the methylguanine-O6-DNA-methyltransferase gene by COBRA and subsequent native capillary gel electrophoresis.” Electrophoresis 2015. doi: 10.1002/elps.201500242.
• John, C., Herz, T., Boos, J., Langer, K., and Hempel, G. 2015. “A novel asymmetrical flow field-flow fractionation for the analysis of PEG asparaginase.” Talanta 146: 335–339.
• Horn, D, and Hempel, G. 2015. “Spesis.” in Angewandte Pharmakotherapie, edited by O Rose and K Friedland. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
• Hempel, G, and Ritter, J. 2015. “Leukämie.” in Angewandte Pharmakotherapie, edited by O Rose and K Friedland. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
• Waltering, I, Schwalbe, O, and Hempel, G. 2015. “Discrepancies on Medication Plans detected in German Community Pharmacies.” Journal of Evaluation in Clinical Practice 21 (21(5)): 886–892.
• Völler, S, Boos, J.Krischke M, Würthwein, G, Kontny, NE, Boddy, AV, and Hempel, G. 2015. “Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer.” Clinical Pharmacokinetics 54: 1139–1149. doi: 10.1007/s40262-015-0272-4.
• Stader, F, Wuerthwein, G, Groll, AH, Vehreschild, JJ, Cornely, OA, and Hempel, G. 2015. “Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.” Pharmaceutical Research 32: 2029–2037.
• Drogouti, E., Pana, Z., Tragiannidis, A., Hempel, G., and Groll, A. 2015. “Clinical pharmacology of itraconazole in children and adolescents.” Current Fungal Infection Reports 9 (2): 65–73. doi: 10.1007/s12281-015-0218-1.

2014

• Bernemann, C, Hülswig, C, Ruckert, C, Schäfer, S, Blümel, L, Hempel, G, Götte, M, Greve, B, Barth, PJ, Kiesel, L, and Liedtke, C. 2014. “Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.” Molecular Cancer 2014 (13): 174.. doi: 10.1186/1476-4598-13-174.
• Kerl, K, Diestelhorst, C, Bartelink, I, Boelens, J, Trame, MN, Boos, J, and Hempel, G. 2014. “Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients.” Pediatric blood & cancer 61 (2): 306–311. doi: 10.1002/pbc.24827.
• Hempel, G. 2014. “Physiology-Based Pharmacokinetic Modeling - Promise for Paediatric Drug Development?” Current Fungal Infection Reports 8: 67–71.
• Geier, AS, Wellmann, I, Wellmann, J, Kajüter, H, Heidinger, O, Hempel, G, and Hense, HW. 2014. “Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus.” Diabetes Research and Clinical Practice 106: 73–80.
• Diestelhorst, C, Boos, J, McCune, JS, Russell, J, Kangarloo, SB, and Hempel, G. 2014. “Predictive Performance of a Physilogocally Based Pharmacokinetic Model of Busulfan in Children.” Pediatric Hematology-Oncology 2014 (31(8)): 731–742. doi: 10.3109/08880018.2014.927945.
• Dickschen, K, Eissing, T, Mürdter, T, Schwab, M, Willmann, S, and Hempel, G. 2014. “Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.” SpringerPlus 5 (3): 285..
• Borghorst, S, Hempel, G, Poppenborg, S, Franke, D, König, T, and Baumgart, J. 2014. “Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli L-asparaginase preparation (MC0609) in Beagle dog.” Cancer Chemotherapy and Pharmacology 74: 367–378.
• Diestelhorst, C, Boos, J, McCune, JS, and Hempel, G. 2014. “Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM model to optimize dosing.” European Journal of Clinical Pharmacology 70 (7): 839–847. doi: 10.1007/s00228-014-1692-z.
• Kerl, K, Diestelhorst, C, Bartelink, I, Boelens, J, Trame, MN, Boos, J, and Hempel, G. 2014. “Evaluation of effects of busulfan and DMA on SOS in pedriatic stem cell recipients.” Pediatric Blood and Cancer 61: 306–311. doi: 10.1002/pbc.24827.

2013

• Henschel, AD, Rothenberger, LG, Schrey, D, Gerß, J, Hempel, G, and Boos, J. 2013. “Risk and benefit from clinical trials in minors: Making the case for transparent and consistent publications.” Open Journal of Pediatrics 03 (02): 151–164. doi: 10.4236/ojped.2013.32027.
• Trame, MN, Bartelink, IH, Boos, J, Boelens, JJ, and Hempel, G. 2013. “Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration.” Cancer Chemotherapy and Pharmacology 72 (5): 1149–1155. doi: 10.1007/s00280-013-2284-9.
• Diestelhorst, C, Boos, J, McCune, JS, Russell, J, Kangarloo, SB, and Hempel, G. 2013. “Physiologically based pharmacokinetic modelling of Busulfan: A new approach to describe and predict the pharmacokinetics in adults.” Cancer Chemotherapy and Pharmacology 72 (5): 991–1000. doi: 10.1007/s00280-013-2275-x.
• Geier, A.S., Wellmann, J., Wellmann, I., Kajuter, H., Heidinger, O., Hempel, G., and Hense, H.W. 2013. “Cancer detection rates following enrolment in a disease management programme for type 2 diabetes.” Diabetologia 56 (9): 1944–1948. doi: 10.1007/s00125-013-2947-4.
• Kontny, NE, Würthwein, G, Boos, J, Boddy, AV, Krischke, M, Fuhr, U, Thompson, PA, Jörger, M, Schellens, JH, and Hempel, G. 2013. “Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.” Cancer Chemotherapy and Pharmacology 71 (3): 749–763. doi: 10.1007/s00280-013-2069-1.
• Würthwein, G, Cornely, OA, Trame, M, Vehreschild, JJ, Vehreschild, MJ, Farowski, F, Müller, C, Boos, J, Hempel, G, Hallek, M, and Groll, AH. 2013. “Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.” Antimicrobial Agents and Chemotherapy 57 (4): 1664–1671.

2012

• Storzinger, D., Borghorst, S., Hofer, S., Busch, C.J., Lichtenstern, C., Hempel, G., Weigand, M.A., and Hoppe-Tichy, T. 2012. “Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit.” Antimicrobial Agents and Chemotherapy 56 (8): 4468–4470. doi: 10.1128/AAC.06167-11.
• Dickschen, K., Willmann, S., Thelen, K., Lippert, J., Hempel, G., and Eissing, T. 2012. “Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance.” Frontiers in Pharmacology null (null). doi: 10.3389/fphar.2012.00092.
• Falck, E., Groenhagen, A., Muhlisch, J., Hempel, G., and Wunsch, B. 2012. “Genome-wide DNA methylation level analysis by micellar electrokinetic chromatography and laser-induced fluorescence detection after treatment of cell lines with azacytidine and antifolates.” Analytical Biochemistry 421 (2): 439–445. doi: 10.1016/j.ab.2011.09.027.
• Fischer, U., Schuler, K., Siebert, S., Smollich, M., Elkeles, B., Hempel, G., and Kruse, J. 2012. “Formulation - Quality in seven steps. Step 1: Comply with hygiene standards.” Deutsche Apotheker-Zeitung 152 (37): 62–73.
• Bartelink, I.H., Boelens, J.J., Bredius, R.G.M., Egberts, A.C.G., Wang, C., Bierings, M.B., Shaw, P.J., Nath, C.E., Hempel, G., Zwaveling, J., Danhof, M., and Knibbe, C.A.J. 2012. “Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: Towards individualized dosing.” Clinical Pharmacokinetics 51 (5): 331–345. doi: 10.2165/11598180-000000000-00000.
• Trame, MN, Bergstrand, M, Karlsson, MO, and Hempel, G. 2012. “Population Pharmacokinetics of Busulfan in Children-Response.” Clinical Cancer Research 18 (9): 2717–2718. doi: 10.1158/1078-0432.CCR-12-0425.
• Kontny, NE, Boos, J, Würthwein, G, Hempel, G, Boddy, AV, Groll, AH, and Krischke, M. 2012. “Minization of the preanalytical error in pharmacokinetic analyses and therapeutic drug monitoring: focus on IV drug administration.” Therapeutic Drug Monitoring 34 (4): 460–466. doi: 10.1097/FTD.0b013e31825a4d9c.
• Borghorst, S, Pieters, R, Kuehnel, HJ, Boos, J, and Hempel, G. 2012. “Population pharmacokinetics of native Escheria coli asparaginase.” Clinical Trials 29 (2): 154–165. doi: 10.3109/08880018.2011.627978.
• Siebert, S, Elkeles, B, Hempel, G, Kruse, J, and Smollich, M. 2012. “Die PRISCUS-Liste im klinischen Test; Praktikabilität und Vergleich mit internationalen PIM-Listen.” Zeitschrift für Gerontologie und Geriatrie 46: 35–47.
• Reimer, J, Bien, S, Ameling, S, Hammer, E, Völker, U, Hempel, G, Boss, J, Kroemer, HK, and Ritter, CA. 2012. “Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.” European Journal of Clinical Pharmacology 68 (6): 923–935. doi: 10.1007/s00228-011-1209-y.
• Kersting, G, Willmann, S, Würthwein, G, Lippert, J, Boos, J, and Hempel, G. 2012. “Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.” Cancer Chemotherapy and Pharmacology 69 (2): 397–405. doi: 10.1007/s00280-011-1706-9.
• Würthwein, G, Young, C, Lanvers-Kaminsky, C, Hempel, G, Trame, M, Schwerdtfeger, R, Ostermann, H, Heinz, W, Cornely, O, Kolve, H, Boos, J, Silling, G, and Groll, A. 2012. “Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.” Antimicrobial Agents and Chemotherapy 56 (1): 536–543. doi: 10.1128/AAC.00265-11.

2011

• Hempel, G., and Trame, M.N. 2011. “Therapeutic drug monitoring of busulfan.” Clinical Chemistry 57 (4): 643–644. doi: 10.1373/clinchem.2010.155374.
• Trame, MN, Bergstrand, M, Karlsson, MO, Boos, J, and Hempel, G. 2011. “Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.” Clinical Cancer Research 17 (21): 6867–6877. doi: 10.1158/1078-0432.CCR-11-0074.
• Hempel, G, and Baum, S, eds. 2011. Geriatrische Pharmazie. Preprint. Govi-Verlag: Govi.
• Horn, DG, Trame, MN, and Hempel, G. 2011. “The management of hypertensive emergencies in children after stem cell transplantation.” International Journal of Clinical Pharmacy 33: 165–176.
• Kontny, NE, Hempel, G, Boos, J, Boddy, AV, and Krischke, M. 2011. “Minimization of the preanalytical error in plasma samples for pharmacokinetic analyses and therapeutic drug monitoring-using doxorubicin as an example.” Therapeutic Drug Monitoring 33 (6): 766–771. doi: 10.1097/FTD.0b013e31823aa8ab.

2010

• Swoboda, S, Ober, MC, Lichtenstern, C, Saleh, S, Schwenger, V, Sonntag, H-G, Haefeli, WE, Hempel, G, Hoppe-Tichy, T, and Weigand, MA. 2010. “Pharmacokinetics of linezolid in septic patients with and without extended dialysis.” European Journal of Clinical Pharmacology 66 (3): 291–298. doi: 10.1007/s00228-009-0766-9.
• Trame, MN, Mitchell, L, Krümpel, A, Male, C, Hempel, G, and Nowak-Göttl, U. 2010. “Population pharmacokinetics of enoxaparin in infants, children and adolescents during secondary thromboembolic prophylaxis: A cohort study.” Journal of Thrombosis and Haemostasis 8 (9): 1950–1958. doi: 10.1111/j.1538-7836.2010.03964.x.
• Hempel, G, Müller, HJ, Lanvers-Kaminsky, C, Würthwein, G, Hoppe, A, and Boos, J. 2010. “A population pharmacokinetic model for pegylated-asparaginase in children.” British Journal of Haematology 148 (1): 119–125. doi: 10.1111/j.1365-2141.2009.07923.x.
• Hempel, G, Relling, MV, de Rossi, G, Stary, J, De Lorenzo, P, Valsecchi, MG, Barisone, E, Boos, J, and Pieters, R. 2010. “Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol.” Pediatric Blood and Cancer 54 (3): 355–360. doi: 10.1002/pbc.22266.
• Schrey, D, Borghorst, S, Lanvers-Kaminsky, C, Hempel, G, Gerss, J, Möricke, A, Schrappe, M, and Boos, J. 2010. “Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.” Pediatric Blood and Cancer 54 (7): 952–958. doi: 10.1002/pbc.22417.
• Niemann, A, Mühlisch, J, Frühwald, MC, Gerss, J, Hempel, G, and Boos, J. 2010. “Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?” Therapeutic Drug Monitoring 32 (4): 467–475. doi: 10.1097/FTD.0b013e3181e5c6b3.

2009

• Goedecke, S, Schlosser, S, Muhlisch, J, Hempel, G, Fruhwald, MC, and Wünsch, B. 2009. “Determination of DNA methylation by COBRA: A comparative study of CGE with LIF detection and conventional gel electrophoresis.” Electrophoresis 30 (17): 3063–3070. doi: 10.1002/elps.200900204.
• Schrauder, A, Saleh, S, Sykora, KW, Hoy, H, Welte, K, Boos, J, Hempel, G, and Grigull, L. 2009. “Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough.” Pediatric Transplantation 13 (4): 444–450. doi: 10.1111/j.1399-3046.2008.00968.x.
• Goedecke, S, Schlosser, S, Mühlisch, J, Hempel, G, Frühwald, MC, and Wünsch, B. 2009. “Accurate quantification of DNA methylation of DRD4 applying capillary gel electrophoresis with LIF detection.” Electrophoresis 30 (8): 1412–1417. doi: 10.1002/elps.200800567.
• Groll, AH, Young, C, Lanvers-Kaminsky, C, Silling, G, Hempel, G, Boos, J, and Wurthwein, G. 2009. “Population pharmacokinetics of liposomal amphotericin B, caspofungin and the combination of both in allogeneic hematopoietic stem cell recipients.” contribution to the 4th Trends in Medical Mycology, Athen, Deutschland doi: 10.1111/j.1439-0507.2009.01782.x.

2008

• Koling, S, and Hempel, G. 2008. “Arzneimitteltherapie im Kindesalter: Die sichere und effektive Dosis finden.” Pz Prisma 15 (2): 68–78.
• Groenhagen, A, Kallinger, B, Hempel, G, Lanvers-Kaminsky, C, Muhlisch, J, Boos, J, Jurgens, H, and Fruhwald, MC. 2008. “The impact of antifolate therapy on the genome and epigenome.” Klinische Pädiatrie 220 (3): 201–201..
• Niemann, A, Boos, J, Muhlisch, J, Fruhwald, MC, and Hempel, G. 2008. “Determination of methotrexate and its main metabolite in cerebrospinal fluid after High-Dose Methotrexate by LC-MS.” Klinische Pädiatrie 220 (3): 205–205..

2007

• Hempel, G, and Boos, J. 2007. “Comment on "Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation" by F.K. Glowka et al. [J. Chromatogr. B 850 (2007) 569-574].” Journal of Chromatography B 853 (1-2): 369–370.
• Hempel, G, Oechtering, D, Lanvers-Kaminsky, C, Klingebiel, T, Vormoor, J, Gruhn, B, and Boos, J. 2007. “Cytotoxicity of dimethylacetamide and pharmacokinetics in children receiving intravenous busulfan.” Journal of Clinical Oncology 25 (13): 1772–1778. doi: 10.1200/JCO.2006.08.8807.
• Hempel, G, and Boos, J. 2007. “Flat-fixed dosing versus body surface area-based dosing of anticancer drugs: There is a difference.” Oncologist 12 (8): 924–926. doi: 10.1634/theoncologist.12-8-924.
• Koling, S, Hempel, G, Lanvers, C, Boos, J, and Würthwein, G. 2007. “Monitoring paracetamol metabolism after single and repeated administration in pediatric patients with neoplastic diseases.” International Journal of Clinical Pharmacology and Therapeutics 45 (9): 496–503. doi: 10.5414/cpp45496.
• Hunz, M, Jetter, A, Warm, M, Pantke, E, Tuscher, M, Hempel, G, Jaehde, U, Untch, M, Kurbacher, C, and Fuhr, U. 2007. “Plasma and tissue pharmacokinetics of epirubicin and paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.” Clinical Pharmacology and Therapeutics 81 (5): 659–668. doi: 10.1038/sj.clpt.6100067.
• Joerger, M, Huitema, ADR, Richel, DJ, Dittrich, C, Pavlidis, N, Briasoulis, E, Vermorken, JB, Strocchi, E, Martoni, A, Sorio, R, Sleeboom, HP, Izquierdo, MA, Jodrell, DI, Féty, R, De Bruijn, E, Hempel, G, Karlsson, M, Tranchand, B, Schrijvers, AHGJ, Twelves, C, Beijnen, JH, and Schellens, JHM. 2007. “Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG.” Clinical Pharmacokinetics 46 (12): 1051–1068. doi: 10.2165/00003088-200746120-00005.
• Wilde, S, Jetter, A, Rietbrock, S, Kasel, D, Engert, A, Josting, A, Klimm, B, Hempel, G, Reif, S, Jaehde, U, Merkel, U, Busse, D, Schwab, M, Diehl, V, and Fuhr, U. 2007. “Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.” Clinical Pharmacokinetics 46 (4): 319–333. doi: 10.2165/00003088-200746040-00005.
• Armstrong, JK, Hempel, G, Koling, S, Chan, LS, Fisher, T, Meiselman, HJ, and Garratty, G. 2007. “Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.” Cancer 110 (1): 103–111. doi: 10.1002/cncr.22739.
• Joerger, M, Huitema, ADR, Richel, DJ, Dittrich, C, Pavlidis, N, Briasoulis, E, Vermorken, JB, Strocchi, E, Martoni, A, Sorio, R, Sleeboom, HP, Izquierdo, MA, Jodrell, DI, Calvert, AH, Boddy, A, Hollema, H, Fety, R, Van der, Vijgh W JF, Hempel, G, Chatelut, E, Karlsson, M, Tranchand, B, Schrijvers, AHGJ, Beijnen, JH, and Schellens, JHM. 2007. “Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG.” British Journal of Clinical Pharmacology 63 (4): 505–505. doi: 10.1111/j.1365-2125.2007.02886_4.x.
• Hempel, G, and Boos, J. 2007. “Comment on "Determination of treosulfan in plasma and urine by HPLC with refractometric detection; pharmacokinetic studies in children undergoing myeloablative treatment prior to haematopoietic stem cell transplantation" by F.K. Glowka et al. J. Chromatogr. B 850 (2007) 569-574.” Journal of Chromatography B 853 (1-2): 369–370. doi: 10.1016/j.jchromb.2007.02.060.
• Hempel, G, and Boos, J. 2007. “Flat-fixed dosing versus body surface area based dosing of anticancer drugs: there is a difference.” Oncologist 12 (8): 924–926. doi: 10.1634/theoncologist.12-8-924.
• Hempel, G. 2007. “Populationspharmakokinetik.” in Repetitorium Klinische Pharmazie, edited by P Högger and E Strehl. Eschborn: Govi.
• Hempel, G. 2007. “Pharmakogenetik.” in Repetitorium Klinische Pharmazie, edited by P Högger and E Strehl. Eschborn: Govi.

2006

• Ünsalan, S, Hempel, G, Fobker, M, Würthwein, G, and Boos, J. 2006. “Monitoring of mycophenolic acid in the plasma of transplant patients by capillary electrophoresis.” Chromatographia 64 (7-8): 419–421. doi: 10.1365/s10337-006-0046-0.
• Oechtering, D, Boos, J, and Hempel, G. 2006. “Monitoring of N,N-dimethylacetamide in children during i.v.-busulfan therapy by liquid chromatography-mass spectrometry.” Journal of Chromatography B 838 (2): 129–134. doi: 10.1016/j.jchromb.2006.04.034.
• Saleh, S, and Hempel, G. 2006. “Quantification of ganciclovir in human plasma using capillary electrophoresis.” Electrophoresis 27 (12): 2439–2443. doi: 10.1002/elps.200500903.
• Lanvers-Kaminsky, C, and Hempel, G. 2006. “Preclinical and Clinical Aspects of Asparaginase.” European Journal of Hospital Pharmacy: Science and Practice 12 (5): 45–46.
• Hempel, G. 2006. “Kommentar zur Monographie Buspironhydrochlorid des Europäischen Arzneibuchs.” in Kommentar zum Ph. Eur. Ausgabe 5.4, edited by G Scriba. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
• Hempel, G. 2006. “Kommentar zur Monographie Emedastindifumarat des Europäischen Arzneibuchs.” in Kommentar zum Ph. Eur. Ausgabe 5.4, edited by G Scriba. Stuttgart: Wissenschaftliche Verlagsgesellschaft.

2005

• Lingg, RM, Hempel, G, Rots, MG, Van Zantwijk, CH, Boos, J, and Kaspers, GJL. 2005. “Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay.” Cancer Chemotherapy and Pharmacology 56 (3): 322–327. doi: 10.1007/s00280-005-1032-1.
• Hempel, G, Lingg, R, and Boos, J. 2005. “Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: Implications for the application in case of methotrexate intoxications.” Cancer Chemotherapy and Pharmacology 55 (4): 347–353. doi: 10.1007/s00280-004-0910-2.
• Oechtering, D, Schiltmeyer, B, Hempel, G, Schwab, M, Würthwein, G, Mürdter, T, Klingebiel, T, Vormoor, J, Gruhn, B, Fleischack, G, and Boos, J. 2005. “Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation.” Anti-Cancer Drugs 16 (3): 337–344. doi: 10.1097/00001813-200503000-00014.
• Würthwein, G, Koling, S, Reich, A, Hempel, G, Schulze-Westhoff, P, Pinheiro, PV, and Boos, J. 2005. “Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery.” European Journal of Clinical Pharmacology 60 (12): 883–888. doi: 10.1007/s00228-004-0873-6.
• Würthwein, G, Groll, AH, Hempel, G, Adler-Shohet, FC, Lieberman, JM, and Walsh, TJ. 2005. “Population pharmacokinetics of amphotericin B lipid complex in neonates.” Antimicrobial Agents and Chemotherapy 49 (12): 5092–5098. doi: 10.1128/AAC.49.12.5092-5098.2005.
• Würthwein, G, Koling, S, Reich, A, Hempel, G, Schulze-Westhoff, P, Pinheiro, PV, and Boos, J. 2005. “Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery.” European Journal of Clinical Pharmacology 60 (12): 883–888. doi: 10.1007/s00228-004-0873-6.

2004

• Hempel, G. 2004. “Dose and therapy individualisation in cancer chemotherapy.” in Drug Monitoring and Clinical Chemistry, Handbook of Analytical Seperations Vol 5, edited by G Hempel. Amsterdam: Elsevier. doi: 10.1016/S1567-7192(04)80008-1.

2003

• Flege, S, Griese, N, and Hempel, G. 2003. “Drug Monitoring von Anthrazyklinen: Teil 1: Chemie, Wirkung, Nebenwirkung und Pharmakokinetik.” Pz Prisma 10 (1): 29–36.
• Flege, S, Griese, N, and Hempel, G. 2003. “Drug Monitoring von Anthrazyklinen Teil 2: Monitoring bei Kindern, Reduktion der Kardiotoxizität, Fallbeispiele.” Pz Prisma 10 (2): 105–117.
• Hempel, G, Reinhardt, D, Creutzig, U, and Boos, J. 2003. “Population pharmacokinetics of liposomal daunorubicin in children.” British Journal of Clinical Pharmacology 56 (4): 370–377. doi: 10.1046/j.1365-2125.2003.01886.x.
• Hempel, G, Rübe, C, Mosler, C, Wienstroer, M, Wagner-Bohn, A, Schuck, A, Willich, N, and Boos, J. 2003. “Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors.” Anti-Cancer Drugs 14 (6): 417–422. doi: 10.1097/00001813-200307000-00005.
• Schiltmeyer, B, Klingebiel, T, Schwab, M, Mürdter, TE, Ritter, CA, Jenke, A, Ehninger, G, Gruhn, B, Würthwein, G, Boos, J, and Hempel, G. 2003. “Population pharmacokinetics of oral busulfan in children.” Cancer Chemotherapy and Pharmacology 52 (3): 209–216. doi: 10.1007/s00280-003-0631-y.
• Hempel, G. 2003. “Biomedical applications of capillary electrophoresis.” Clinical Chemistry and Laboratory Medicine 41 (6): 720–723. doi: 10.1515/CCLM.2003.111.

2002

• Griese, N, Blaschke, G, Boos, J, and Hempel, G. 2002. “Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis.” Journal of Chromatography A 979 (1-2): 379–388. doi: 10.1016/S0021-9673(02)01440-1.
• Lingg, RM, Rots, MG, Van Zantwijk, CH, Hempel, G, Kaspers, GJL, and Boos, J. 2002. “Effect and interaction of 7-hydroxy methotrexate and methotrexate in AML and ALL patients samples: Measured by the thymidylate synthase inhibition assay.” International Journal of Clinical Pharmacology and Therapeutics 40 (8): 382–384.
• Hempel, G, Flege, S, Würthwein, G, and Boos, J. 2002. “Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.” Cancer Chemotherapy and Pharmacology 49 (2): 133–141. doi: 10.1007/s00280-001-0392-4.
• Busse, D, Würthwein, G, Hinske, C, Hempel, G, Fromm, MF, Eichelbaum, M, Kroemer, HK, and Busch, FW. 2002. “Pharmacokinetics of intravenous etoposide in patients with breast cancer: Influence of dose escalation and cyclophosphamide and doxorubicin coadministration.” Naunyn-Schmiedeberg's Archives of Pharmacology 366 (3): 218–225. doi: 10.1007/s00210-002-0594-2.
• Schiltmeyer, B, Hempel, G, Schwab, M, Ritter, C, Klingebiel, T, and Boos, J. 2002. “Population pharmacokinetics of oral busulfan in children.” International Journal of Clinical Pharmacology and Therapeutics 40 (8): 385–386.
• Reinhardt, D, Hempel, G, Fleischhack, G, Schulz, A, Boos, J, and Creutzig, U. 2002. “Effektive Rezidivtherapie der akuten myeloischen Leukämie im Kindesalter mit liposomalem Daunorubicin und Cytarabin.” Klinische Pädiatrie 214 (4): 188–194. doi: 10.1055/s-2002-33185.
• Wilde, S, Jetter, A, Zaigier, M, Rietbrock, S, Menzel, H, Sieber, M, Tesch, H, Hempel, G, Busse, D, Schwab, M, Reif, S, Jaehde, U, Diehl, V, and Fuhr, U. 2002. “Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy.” International Journal of Clinical Pharmacology and Therapeutics 40 (12): 586–588.
• Lanvers, C, Pinheiro, JPV, Hempel, G, Wuerthwein, G, and Boos, J. 2002. “Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum.” Analytical Biochemistry 309 (1): 117–126. doi: 10.1016/S0003-2697(02)00232-4.